NeuroPace (NPCE) Free Cash Flow Growth (3y) (2023 - 2026)
NeuroPace (NPCE) Free Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.59 Bn | 176.29 Bn | 6.27 Bn | 6.28% |
| 2 | Stryker | 129.07 Bn | 126.19 Bn | 3.81 Bn | 9.63% |
| 3 | Medtronic | 108.58 Bn | 99.36 Bn | 6.41 Bn | 0.05% |
| 4 | Boston Scientific | 68.64 Bn | 67.19 Bn | 3.61 Bn | 29.36% |
| 5 | Edwards Lifesciences | 48.38 Bn | 44.71 Bn | 1.29 Bn | -27.72% |
| 6 | Dexcom | 28.35 Bn | 27.23 Bn | 750.30 Mn | 77.20% |
| 7 | GE HealthCare Technologies | 28.13 Bn | 25.84 Bn | 1.98 Bn | -29.89% |
| 8 | Smith & Nephew | 26.90 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 24.27 Bn | 21.15 Bn | 2.07 Bn | -0.27% |
| 10 | NeuroPace | 517.55 Mn | 463.57 Mn | 18.05 Mn | 15.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.09% |
| Dec 31, 2025 | 27.04% |
| Sep 30, 2025 | 34.42% |
| Jun 30, 2025 | 41.45% |
| Mar 31, 2025 | 12.96% |
| Dec 31, 2024 | 19.36% |
| Sep 30, 2024 | 25.18% |
| Jun 30, 2024 | 12.84% |
| Mar 31, 2024 | -8.59% |
| Dec 31, 2023 | 19.85% |
| Sep 30, 2023 | 24.59% |
| Jun 30, 2023 | -10.08% |
| Mar 31, 2023 | -14.69% |